Pfenex“fully supports” partner Alvogen’s decision to launch the firms’ Bonsity (teriparatide) 505(b)(2) new drug application product in the US, as the clock ticks on a designation of therapeutic equivalence with Eli Lilly’s Forteo (teriparatide) reference brand.
The US-based firm, which celebrated transitioning to a commercial pharma company in the second quarter of this year, is eligible...




